Artivion Balance Sheet Health

Financial Health criteria checks 3/6

Artivion has a total shareholder equity of $304.7M and total debt of $314.0M, which brings its debt-to-equity ratio to 103%. Its total assets and total liabilities are $803.1M and $498.4M respectively. Artivion's EBIT is $28.9M making its interest coverage ratio 1. It has cash and short-term investments of $56.2M.

Key information

103.0%

Debt to equity ratio

US$313.97m

Debt

Interest coverage ratio1x
CashUS$56.17m
EquityUS$304.74m
Total liabilitiesUS$498.41m
Total assetsUS$803.14m

Recent financial health updates

Recent updates

When Should You Buy Artivion, Inc. (NYSE:AORT)?

Nov 07
When Should You Buy Artivion, Inc. (NYSE:AORT)?

Returns At Artivion (NYSE:AORT) Are On The Way Up

Sep 28
Returns At Artivion (NYSE:AORT) Are On The Way Up

Estimating The Intrinsic Value Of Artivion, Inc. (NYSE:AORT)

Sep 06
Estimating The Intrinsic Value Of Artivion, Inc. (NYSE:AORT)

Is Artivion (NYSE:AORT) A Risky Investment?

Jun 28
Is Artivion (NYSE:AORT) A Risky Investment?

Data-Driven Growth Fuels More Upside For Overlooked Artivion

Jun 21

Artivion's (NYSE:AORT) Returns On Capital Are Heading Higher

May 08
Artivion's (NYSE:AORT) Returns On Capital Are Heading Higher

Is Artivion (NYSE:AORT) Using Too Much Debt?

Jan 13
Is Artivion (NYSE:AORT) Using Too Much Debt?

Artivion Stock: A First Assessment

Dec 27

Investors Still Aren't Entirely Convinced By Artivion, Inc.'s (NYSE:AORT) Revenues Despite 27% Price Jump

Nov 23
Investors Still Aren't Entirely Convinced By Artivion, Inc.'s (NYSE:AORT) Revenues Despite 27% Price Jump

Artivion's Ongoing Clinical Studies Could Drive Significant Growth Starting In 2025

Oct 13

Artivion: On-X Sales Double 5-Year Average, Far More Constructive View (Rating Upgrade)

Jul 20

Artivion's (NYSE:AORT) Returns On Capital Are Heading Higher

May 10
Artivion's (NYSE:AORT) Returns On Capital Are Heading Higher

Artivion (NYSE:AORT) Has A Somewhat Strained Balance Sheet

Mar 09
Artivion (NYSE:AORT) Has A Somewhat Strained Balance Sheet

Artivion Non-GAAP EPS of $0.10 beats by $0.12, revenue of $79.4M misses by $0.77M

Feb 16

Artivion: PROACT Xa Overhang Remains Well In Situ, Reaffirm Hold

Dec 18

Artivion (NYSE:AORT) Is Making Moderate Use Of Debt

Sep 29
Artivion (NYSE:AORT) Is Making Moderate Use Of Debt

Artivion: Stopping PROACT Xa Trial Removes Long-Term Growth Driver

Sep 27

Artivion Non-GAAP EPS of -$0.03 misses by $0.06, revenue of $80.34M beats by $3.07M

Aug 04

Financial Position Analysis

Short Term Liabilities: AORT's short term assets ($288.0M) exceed its short term liabilities ($152.8M).

Long Term Liabilities: AORT's short term assets ($288.0M) do not cover its long term liabilities ($345.6M).


Debt to Equity History and Analysis

Debt Level: AORT's net debt to equity ratio (84.6%) is considered high.

Reducing Debt: AORT's debt to equity ratio has increased from 77.8% to 103% over the past 5 years.


Balance Sheet


Cash Runway Analysis

For companies that have on average been loss-making in the past, we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: Whilst unprofitable AORT has sufficient cash runway for more than 3 years if it maintains its current positive free cash flow level.

Forecast Cash Runway: AORT is unprofitable but has sufficient cash runway for more than 3 years, even with free cash flow being positive and shrinking by 11.8% per year.


Discover healthy companies